480998-12-7

Basic information

• Product Name: INNO-206 HCl salt/INNO206 HCl salt
• Synonyms: INNO-206 HCl salt/INNO206 HCl salt;INNO-206 HCI;2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide monohydrochloride;INNO-206 monohydrochloride;Aldoxorubicin·HCl;Aldoxorubicin Hydrochloride;INNO-206 hydrochloride
• CAS NO: 480998-12-7
• Molecular Formula: C37H42N4O13.HCl
• Mol File: 480998-12-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: INNO-206 HCl salt/INNO206 HCl salt(CAS DataBase Reference)
• NIST Chemistry Reference: INNO-206 HCl salt/INNO206 HCl salt(480998-12-7)
• EPA Substance Registry System: INNO-206 HCl salt/INNO206 HCl salt(480998-12-7)

Safety Data

• Hazardous Substances Data: 480998-12-7(Hazardous Substances Data)

Usage

General Description

INNO-206 HCl salt, also known as INNO206 HCl salt, is a prodrug of doxorubicin, a potent chemotherapeutic agent commonly used in the treatment of various types of cancer. INNO-206 HCl salt/INNO206 HCl salt is designed to have improved safety and effectiveness compared to traditional doxorubicin, as it is intended to be activated specifically within the tumor microenvironment, reducing the potential for off-target toxicity. INNO-206 HCl salt is believed to be more stable in the bloodstream and to have enhanced tumor penetration and retention, allowing for improved anticancer activity while minimizing side effects. Clinical trials have shown promising results in the treatment of different types of cancer, making it a potential candidate for further development as a novel chemotherapy option.